PGNX News and Press, Progenics Pharmaceuticals Inc. From 06/03/19

Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company de...

NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at t...

NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting AZEDRA (iobenguane I 131) and...

ALPHARETTA, Ga. , May 22, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), announced today that it...

In my last Progenics Pharmaceuticals ( PGNX ) article , I laid out my reasoning for starting a pilot position prior to the Q4/2018 ER. The share price was bargain-basement levels and the company's projected revenue was attractive. I was confident in the technical entry and the approaching ear...

NEW YORK & DRESDEN, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, and ROTOP Pharmaka GmbH, a leading radiopharmaceuticals...

ALPHARETTA, Ga. , May 13, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics", "you" or the "Company")(NASDAQ:PGNX), today publicly called on the Company's management...

Progenics Pharmaceuticals, Inc. (PGNX) Q1 2019 Earnings Conference Call May 09, 2019 08:30 AM ET Company Participants Melissa Downs - Head of Investor Relations Mark Baker - Chief Executive Officer Asha Das - Chief Medical Officer Bryce Tenbarge - Senior Vice President, Commerc...

Progenics Pharmaceuticals (NASDAQ: PGNX ): Q1 GAAP EPS of -$0.22 misses by $0.02 . More news on: Progenics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

AZEDRA ® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat Patients Phase 2 Trial of 1095 Initiated with Enrollment to Begin 2Q 2019 Phase 3 CONDOR Trial of PyL TM Enrolling ...